Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma.

Broberg Palmgren, Karin LU orcid ; Höglund, Mattias LU ; Gustafsson, Cecilia LU ; Björk, Jonas LU ; Ingvar, Christian LU ; Albin, Maria LU and Olsson, Håkan LU orcid (2007) In Cancer Letters 258(1). p.38-44
Abstract
The newly identified protein BLAP75/RMI1 associates with the helicase BLM and is critical for the function of the homologous recombination complex. Mutations altering BLM function are associated with highly elevated cancer susceptibility (Bloom's syndrome). We have analyzed the common polymorphism Ser455Asn in RMI1 and its association with cancer risk in acute myeloid leukemia (AML, N=93), myelodysplatic syndromes (MDS, N=74), and malignant melanoma (MM, N=166). Two control groups were used: one population-based (N=119) and one recruited from spouses of cancer patients (N=189). The results showed a consistent pattern, where carriers of the Asn variant had a significantly increased risk of AML/MDS. The risk of AML/MDS for SerAsn+AsnAsn... (More)
The newly identified protein BLAP75/RMI1 associates with the helicase BLM and is critical for the function of the homologous recombination complex. Mutations altering BLM function are associated with highly elevated cancer susceptibility (Bloom's syndrome). We have analyzed the common polymorphism Ser455Asn in RMI1 and its association with cancer risk in acute myeloid leukemia (AML, N=93), myelodysplatic syndromes (MDS, N=74), and malignant melanoma (MM, N=166). Two control groups were used: one population-based (N=119) and one recruited from spouses of cancer patients (N=189). The results showed a consistent pattern, where carriers of the Asn variant had a significantly increased risk of AML/MDS. The risk of AML/MDS for SerAsn+AsnAsn subjects was odds ratio (OR)=1.7, 95% confidence interval (CI) 1.1-2.5 or MM was OR=1.5, 95% CI 1.0-2.2. Age might modify the effect of RMI1 on cancer risk. This was most evident for MM: AsnAsn homozygotes > or =64 years showed OR=2.7, 95% CI 1.1-6.0, whereas individuals <64 years showed OR=0.87, 95% CI 0.31-2.5. These results indicate a role of low-penetrance genes involved in BLM-associated homologous recombination for cancer risk. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Acute/genetics* *Male *Melanoma/genetics* *Middle Aged *Myelodysplastic Syndromes/genetics* *Nuclear Proteins/genetics* *Polymerase Chain Reaction *Polymorphism, Genetic *RecQ Helicases *Recombination, Myeloid, *Adenosine Triphosphatases/genetics *Adult *Aged *Aged, 80 and over *Bloom Syndrome/genetics *Carrier Proteins/genetics* *Case-Control Studies *DNA Helicases/genetics *Female *Genetic Variation* *Genotype *Humans *Leukemia, Genetic* *Skin Neoplasms/genetics*
in
Cancer Letters
volume
258
issue
1
pages
38 - 44
publisher
Elsevier
external identifiers
  • wos:000251407200005
  • scopus:35348972879
  • pmid:17900800
ISSN
1872-7980
DOI
10.1016/j.canlet.2007.08.005
language
English
LU publication?
yes
id
b537758e-90b9-4447-aad6-86eb65f8d053 (old id 607469)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17900800&dopt=Abstract
date added to LUP
2016-04-04 09:03:45
date last changed
2022-03-15 17:32:29
@article{b537758e-90b9-4447-aad6-86eb65f8d053,
  abstract     = {{The newly identified protein BLAP75/RMI1 associates with the helicase BLM and is critical for the function of the homologous recombination complex. Mutations altering BLM function are associated with highly elevated cancer susceptibility (Bloom's syndrome). We have analyzed the common polymorphism Ser455Asn in RMI1 and its association with cancer risk in acute myeloid leukemia (AML, N=93), myelodysplatic syndromes (MDS, N=74), and malignant melanoma (MM, N=166). Two control groups were used: one population-based (N=119) and one recruited from spouses of cancer patients (N=189). The results showed a consistent pattern, where carriers of the Asn variant had a significantly increased risk of AML/MDS. The risk of AML/MDS for SerAsn+AsnAsn subjects was odds ratio (OR)=1.7, 95% confidence interval (CI) 1.1-2.5 or MM was OR=1.5, 95% CI 1.0-2.2. Age might modify the effect of RMI1 on cancer risk. This was most evident for MM: AsnAsn homozygotes &gt; or =64 years showed OR=2.7, 95% CI 1.1-6.0, whereas individuals &lt;64 years showed OR=0.87, 95% CI 0.31-2.5. These results indicate a role of low-penetrance genes involved in BLM-associated homologous recombination for cancer risk.}},
  author       = {{Broberg Palmgren, Karin and Höglund, Mattias and Gustafsson, Cecilia and Björk, Jonas and Ingvar, Christian and Albin, Maria and Olsson, Håkan}},
  issn         = {{1872-7980}},
  keywords     = {{Acute/genetics* *Male *Melanoma/genetics* *Middle Aged *Myelodysplastic Syndromes/genetics* *Nuclear Proteins/genetics* *Polymerase Chain Reaction *Polymorphism; Genetic *RecQ Helicases *Recombination; Myeloid; *Adenosine Triphosphatases/genetics *Adult *Aged *Aged; 80 and over *Bloom Syndrome/genetics *Carrier Proteins/genetics* *Case-Control Studies *DNA Helicases/genetics *Female *Genetic Variation* *Genotype *Humans *Leukemia; Genetic* *Skin Neoplasms/genetics*}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{38--44}},
  publisher    = {{Elsevier}},
  series       = {{Cancer Letters}},
  title        = {{Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma.}},
  url          = {{http://dx.doi.org/10.1016/j.canlet.2007.08.005}},
  doi          = {{10.1016/j.canlet.2007.08.005}},
  volume       = {{258}},
  year         = {{2007}},
}